Stocks›Healthcare›BBIO

BBIO BridgeBio Pharma, Inc.

NasdaqResearch view

BridgeBio Pharma, Inc. operates in the Pharmaceutical Preparations industry.

$66.39−1.10%

Oct 16 close · 1D EOD · Databento

HealthcarePharmaceutical PreparationsLarge-capSEC EDGAR FY 2025-12-31

On the WireNo stories on BBIO yet. Follow the company and the next one lands in Following.

What happened

Daily closes · dots are Wire stories

What’s next

Expected around early November, going by its own filing history. The company has not announced a date yet. Its matching report came Oct 29, 2025 and Nov 12, 2024, after the close.

Last report

Aug 10, 2026−1.15%

after the close

Last 4, next close

median 1.87% either way

up 1 of 4

Every report since 2023 →Earnings calendar →

DateEventSourceNext close

Aug 10Earnings release, after the close · 8-KSEC EDGARSEC EDGAR ↗−1.15%

Next close = the first close after the event against the close before it. Prior-session closes only; not a call, not advice.

What happened · big days

22 big days in a year, and what we hold on each

A big day is a close more than 4.24% from the one before, three times BBIO’s median day (1.41%). On 0 of the 22, its peer group moved the same way at least half as far. We show what we hold. We never name a cause.

every other trading daya big day, numbered in the list below±4.24%Hover a bar for its day. Click a big day to open it.

Shaded: since our stories began, Jun 10. Tap a bar for its day.

#DayBBIOWhat we hold that dayGroup (median of 4) · each

1 Oct 27, 2025+17.14%
Before our storiesgroup +0.1%, did not move with it
1Oct 27, 2025+17.14%
Before our stories
+0.1% did not move with itMRK +0.6 · LLY +0.1 · ABBV +0.0 · JNJ −0.1
2 Oct 30, 2025−4.88%
Resultsgroup +1.3%, did not move with it
2Oct 30, 2025−4.88%
ResultsFirst close after the Oct 29 results filing
+1.3% did not move with itMRK −0.3 · JNJ +1.3 · ABBV +1.4 · LLY +3.8
3 Nov 11, 2025+6.00%
Before our storiesgroup +2.9%, did not move with it
3Nov 11, 2025+6.00%
Before our stories
+2.9% did not move with itMRK +4.8 · ABBV +3.0 · JNJ +2.9 · LLY +2.3
4 Nov 21, 2025+5.40%
Before our storiesgroup +2.3%, did not move with it
4Nov 21, 2025+5.40%
Before our stories
+2.3% did not move with itABBV +3.0 · MRK +2.9 · LLY +1.6 · JNJ +0.4
5 Jan 5, 2026−6.15%
Before our storiesgroup −2.5%, did not move with it
5Jan 5, 2026−6.15%
Before our stories
−2.5% did not move with itABBV −4.0 · LLY −3.6 · JNJ −1.5 · MRK +0.9
6 Jan 9, 2026+4.65%
Before our storiesgroup −1.2%, did not move with it
6Jan 9, 2026+4.65%
Before our stories
−1.2% did not move with itMRK −0.4 · JNJ −0.7 · ABBV −1.8 · LLY −2.0
7 Feb 5, 2026−15.24%
Before our storiesgroup +1.0%, did not move with it
7Feb 5, 2026−15.24%
Before our stories
+1.0% did not move with itLLY −7.8 · ABBV +0.9 · MRK +1.2 · JNJ +1.4
8 Feb 6, 2026+6.78%
Before our storiesgroup +1.9%, did not move with it
8Feb 6, 2026+6.78%
Before our stories
+1.9% did not move with itLLY +3.7 · ABBV +2.0 · MRK +1.8 · JNJ +0.9
9 Feb 9, 2026+6.23%
Before our storiesgroup −0.9%, did not move with it
9Feb 9, 2026+6.23%
Before our stories
−0.9% did not move with itABBV −0.1 · JNJ −0.6 · LLY −1.3 · MRK −3.5
10 Feb 19, 2026−4.34%
Before our storiesgroup +0.2%, did not move with it
10Feb 19, 2026−4.34%
Before our stories
+0.2% did not move with itABBV −1.9 · MRK +0.2 · LLY +0.3 · JNJ +0.8
11 Mar 10, 2026+13.22%
Before our storiesgroup −0.1%, did not move with it
11Mar 10, 2026+13.22%
Before our stories
−0.1% did not move with itJNJ +0.5 · MRK −0.0 · ABBV −0.2 · LLY −0.7
12 Mar 12, 2026−4.78%
Before our storiesgroup −0.7%, did not move with it
12Mar 12, 2026−4.78%
Before our stories
−0.7% did not move with itLLY −2.3 · ABBV −1.0 · JNJ −0.4 · MRK −0.3
13 Mar 25, 2026+4.49%
Before our storiesgroup +1.7%, did not move with it
13Mar 25, 2026+4.49%
Before our stories
+1.7% did not move with itMRK +2.6 · JNJ +2.0 · LLY +1.5 · ABBV +1.0
14 Mar 31, 2026+7.06%
Before our storiesgroup +1.9%, did not move with it
14Mar 31, 2026+7.06%
Before our stories
+1.9% did not move with itLLY +3.7 · ABBV +2.0 · MRK +1.9 · JNJ +0.8
15 Apr 13, 2026+4.40%
Before our storiesgroup −0.9%, did not move with it
15Apr 13, 2026+4.40%
Before our stories
−0.9% did not move with itJNJ −0.2 · ABBV −0.7 · MRK −1.1 · LLY −1.1
16 Apr 28, 2026−6.45%
Before our storiesgroup +0.4%, did not move with it
16Apr 28, 2026−6.45%
Before our stories
+0.4% did not move with itMRK −0.2 · ABBV +0.2 · LLY +0.7 · JNJ +1.1
17 May 15, 2026−5.07%
Before our storiesgroup −1.0%, did not move with it
17May 15, 2026−5.07%
Before our stories
−1.0% did not move with itMRK −1.8 · JNJ −1.8 · LLY −0.2 · ABBV −0.2
18 Jul 9, 2026+15.12%
Nothing on BBIOgroup −0.9%, did not move with it
18Jul 9, 2026+15.12%
Nothing on BBIONo BBIO story, brief or results filing in our record that day
−0.9% did not move with itLLY +0.1 · MRK −0.7 · ABBV −1.1 · JNJ −1.6
19 Jul 10, 2026−4.75%
Nothing on BBIOgroup −1.0%, did not move with it
19Jul 10, 2026−4.75%
Nothing on BBIONo BBIO story, brief or results filing in our record that day
−1.0% did not move with itLLY −2.3 · MRK −1.2 · JNJ −0.8 · ABBV −0.7
20 Sep 10, 2026−4.71%
Nothing on BBIOgroup −0.2%, did not move with it
20Sep 10, 2026−4.71%
Nothing on BBIONo BBIO story, brief or results filing in our record that day
−0.2% did not move with itMRK −1.9 · JNJ −0.3 · LLY −0.1 · ABBV +1.6
21 Sep 15, 2026−5.51%
Nothing on BBIOgroup +0.1%, did not move with it
21Sep 15, 2026−5.51%
Nothing on BBIONo BBIO story, brief or results filing in our record that day
+0.1% did not move with itMRK −0.7 · LLY −0.2 · JNJ +0.3 · ABBV +0.5
22 Sep 23, 2026−5.08%
Nothing on BBIOgroup −0.8%, did not move with it
22Sep 23, 2026−5.08%
Nothing on BBIONo BBIO story, brief or results filing in our record that day
−0.8% did not move with itMRK −1.9 · LLY −1.6 · ABBV −0.1 · JNJ −0.0

A story on the same day is not a cause, and a group move is not proof either. Group: the median of LLY, JNJ, ABBV and MRK that day, the largest companies in BBIO’s SEC industry; “moved with BBIO” means the same direction and at least half the size.

What’s next · results

Before the next report: what the first day after the last four did

Six trading days after each results filing (SEC 8-K, Item 2.02). BBIO reports after the close, so day 1 is the next close. Each time, day 6 ended on the same side as day 1.

Reported Jan 12, 2026

day 1+2.95%day 6+1.70%

Reported Feb 24, 2026

day 1−2.59%day 6−2.59%

Reported May 7, 2026

day 1−0.09%day 6−1.96%

Reported Aug 10, 2026

day 1−1.15%day 6−2.00%

Next report: expected early NovemberEstimated from the dates of its last four results filings. Not announced. Since the Aug 10 report: −21.59%. Four reports is a small sample.

Every report since 2023 →

Each line is BBIO’s close against its close before the filing, on licensed end-of-day closes. What happened after each report, not a forecast; a move on the day is not a cause.

The numbers · FY2025, filed

SEC EDGAR

Market cap$13.0B

Revenue$502.1M+126.30%

Net income$-732.9M

EPS, diluted$-3.78−31.20%

Operating margin-104.2%

Return on equity35.3%

Debt / equity-0.97

All filed figures

Snapshot

SEC EDGAR · FY 2025-12-31

SectorHealthcare

Market Cap$13.0B

Enterprise Value$14.4B

Income$-732.9M

Sales$502.1M

Book/sh$-10.62

Cash/sh$2.93

Dividend TTM—

Payout-0%

Employees—

IPO—

Quick Ratio2.68

Current Ratio2.77

Debt/Eq-0.97

EPS (ttm)$-3.78

EPS this Y-31.2%

EPS past 3/5Y—

Sales past 3/5Y86.3%

EPS Y/Y TTM-31.2%

Sales Y/Y TTM126.3%

Shs Outstand195.49M

ROA-78.3%

ROE35.3%

ROIC—

Gross Margin—

Oper. Margin-104.2%

Profit Margin-146.0%

Every figure here is filed with the SEC. Valuation and estimate metrics (P/E, PEG, EV/EBITDA, price targets, forward EPS) are omitted until our market-data feed is licensed for display — we’d rather show fewer numbers than blank ones. Deeper lines (cash flow, balance sheet) below.

Revenue by fiscal year

$69.7M

FY21

$77.6M

FY22

$9.3M

FY23

$221.9M

FY24

$502.1M

FY25

Operating leverage — margins

GrossOperatingNet

Financials, annual · income and cash flowSEC EDGAR · open ▸

Financials — annual

SEC EDGAR · last 5 FY · tap a row to explain it

USD	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	$69.7M	$77.6M	$9.3M	$221.9M	$502.1M
Gross Profit	—	—	—	—	—
Operating Income	$-576.6M	$-512.2M	$-607.4M	$-593.0M	$-523.4M
Net Income	$-586.5M	$-484.6M	$-653.3M	$-543.3M	$-732.9M
Diluted EPS	$-3.90	$-3.26	$-3.95	$-2.88	$-3.78
Operating Cash Flow	$-497.9M	$-419.5M	$-527.7M	$-520.7M	$-445.9M
Free Cash Flow	$-511.2M	$-424.3M	$-529.0M	$-521.7M	$-447.0M

Same industry

BBIO against four drug peers, a year at 100

BBIO is up 20.9% in a year. Merck is up 72.1%, Eli Lilly 56.6%, Johnson & Johnson 32.3% and AbbVie 24.3%. All four did more. Weekly closes, Oct 17, 2025 = 100, on a log scale, so the same percentage move is the same height on every line.

Share this chart

BBIO +20.9%. Merck +72.1%, Eli Lilly +56.6%, Johnson & Johnson +32.3%, AbbVie +24.3%. Weekly closes, Oct 17, 2025 = 100, log scale.

Share this chart

End-of-day closes (Databento EOD), the last close of each week. The four peers are the largest US-listed companies by market value in BBIO’s SEC industry (Pharmaceutical Preparations) with a year of closes. It shows what the closes did; a move here is not a cause, a forecast or a call.

Same industry

In the screener →

LLY$1.18T JNJ$615.9B ABBV$504.4B MRK$360.1B ABT$181.5B PFE$168.6B VRTX$126.7B BMY$122.1B

Build basket with BBIO Screener

Fundamentals sourced from SEC EDGAR filings (public domain). For informational purposes only. Not investment advice.